{"doi":"10.1016/j.esmoop.2021.100230","title":"PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers","abstract":"•Testing for PIK3CA mutations in ctDNA is concordant with testing of tumor tissue.•High PIK3CA-mutant abundance in ctDNA was associated with shorter survival.•Increasing PIK3CA-mutant abundance in serial blood samples was associated with shorter TTF.•Longitudinal monitoring of PIK3CA-mutant ctDNA tracked with cancer clinical course. BackgroundOncogenic mutations in PIK3CA are prevalent in diverse cancers and can be targeted with inhibitors of the phosphoinositide-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Analysis of circulating tumor DNA (ctDNA) provides a minimally invasive approach to detect clinically actionable PIK3CA mutations.Patients and methodsWe analyzed PIK3CA hotspot mutation frequency by droplet digital PCR (QX 200; BioRad) using 16 ng of unamplified plasma-derived cell-free DNA from 68 patients with advanced solid tumors (breast cancer, n = 41; colorectal cancer, n = 13; other tumor types, n = 14). Results quantified as variant allele frequencies (VAFs) were compared with previous testing of archival tumor tissue and with patient outcomes.ResultsOf 68 patients, 58 (85%) had PIK3CA mutations in tumor tissue and 43 (74%) PIK3CA mutations in ctDNA with an overall concordance of 72% (49/68, κ = 0.38). In a subset analysis, which excluded samples from 26 patients known not to have disease progression at the time of sample collection, we found an overall concordance of 91% (38/42; κ = 0.74). PIK3CA-mutated ctDNA VAF of ≤8.5% (5% trimmed mean) showed a longer median survival compared with patients with a higher VAF (15.9 versus 9.4 months; 95% confidence interval 6.7-17.1 months; P = 0.014). Longitudinal analysis of ctDNA in 18 patients with serial plasma collections (range 2-22 time points, median 5) showed that those with a decrease in PIK3CA VAF had a longer time to treatment failure (TTF) compared with patients with an increase or no change (10.7 versus 2.6 months; P = 0.048).ConclusionsDetection of PIK3CA mutations in ctDNA is concordant with testing of archival tumor tissue. Low quantity of PIK3CA-mutant ctDNA is associated with longer survival and a decrease in PIK3CA-mutant ctDNA on therapy is associated with longer TTF. Oncogenic mutations in PIK3CA are prevalent in diverse cancers and can be targeted with inhibitors of the phosphoinositide-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Analysis of circulating tumor DNA (ctDNA) provides a minimally invasive approach to detect clinically actionable PIK3CA mutations. We analyzed PIK3CA hotspot mutation frequency by droplet digital PCR (QX 200; BioRad) using 16 ng of unamplified plasma-derived cell-free DNA from 68 patients with advanced solid tumors (breast cancer, n = 41; colorectal cancer, n = 13; other tumor types, n = 14). Results quantified as variant allele frequencies (VAFs) were compared with previous testing of archival tumor tissue and with patient outcomes. Of 68 patients, 58 (85%) had PIK3CA mutations in tumor tissue and 43 (74%) PIK3CA mutations in ctDNA with an overall concordance of 72% (49/68, κ = 0.38). In a subset analysis, which excluded samples from 26 patients known not to have disease progression at the time of sample collection, we found an overall concordance of 91% (38/42; κ = 0.74). PIK3CA-mutated ctDNA VAF of ≤8.5% (5% trimmed mean) showed a longer median survival compared with patients with a higher VAF (15.9 versus 9.4 months; 95% confidence interval 6.7-17.1 months; P = 0.014). Longitudinal analysis of ctDNA in 18 patients with serial plasma collections (range 2-22 time points, median 5) showed that those with a decrease in PIK3CA VAF had a longer time to treatment failure (TTF) compared with patients with an increase or no change (10.7 versus 2.6 months; P = 0.048). Detection of PIK3CA mutations in ctDNA is concordant with testing of archival tumor tissue. Low quantity of PIK3CA-mutant ctDNA is associated with longer survival and a decrease in PIK3CA-mutant ctDN","journal":"ESMO Open","year":2021,"id":159488,"datarank":0.5641800173540344,"base_score":3.7612001156935624,"endowment":3.7612001156935624,"self_citation_contribution":0.5641800173540344,"citation_network_contribution":0.0,"self_endowment_contribution":0.5641800173540344,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":42,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9597,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":338533,"name":"S. Greg Call","orcid":null,"position":1,"is_corresponding":false},{"id":441162,"name":"Helen J. Huang","orcid":"0000-0002-6308-346X","position":2,"is_corresponding":false},{"id":671489,"name":"A.L. Stuckett","orcid":null,"position":3,"is_corresponding":false},{"id":338534,"name":"Kiran Madwani","orcid":null,"position":4,"is_corresponding":false},{"id":671490,"name":"Abha Adat","orcid":null,"position":5,"is_corresponding":false},{"id":107725,"name":"David S. Hong","orcid":"0000-0001-8721-1609","position":6,"is_corresponding":false},{"id":258839,"name":"Sarina A. Piha‐Paul","orcid":"0000-0001-9455-1660","position":7,"is_corresponding":false},{"id":226642,"name":"Vivek Subbiah","orcid":"0000-0002-6064-6837","position":8,"is_corresponding":false},{"id":266107,"name":"Daniel D. Karp","orcid":"0000-0002-5017-328X","position":9,"is_corresponding":false},{"id":241553,"name":"Siqing Fu","orcid":"0000-0002-1933-0419","position":10,"is_corresponding":false},{"id":266105,"name":"Aung Naing","orcid":"0000-0002-4803-8513","position":11,"is_corresponding":false},{"id":108756,"name":"Apostolia M. Tsimberidou","orcid":"0000-0003-2713-233X","position":12,"is_corresponding":false},{"id":397269,"name":"Stacy Moulder","orcid":"0000-0001-8890-7077","position":13,"is_corresponding":false},{"id":671491,"name":"Kimberly Higginbotham Koenig","orcid":null,"position":14,"is_corresponding":false},{"id":670554,"name":"Carlos H. Bárcenas","orcid":"0000-0001-5377-9167","position":15,"is_corresponding":false},{"id":590669,"name":"Bryan K. Kee","orcid":"0000-0001-5553-2213","position":16,"is_corresponding":false},{"id":397883,"name":"David R. Fogelman","orcid":"0000-0002-4063-189X","position":17,"is_corresponding":false},{"id":241627,"name":"Scott Kopetz","orcid":"0000-0001-9647-3416","position":18,"is_corresponding":false},{"id":70220,"name":"Funda Meric‐Bernstam","orcid":"0000-0001-6816-6072","position":19,"is_corresponding":false},{"id":266117,"name":"Filip Jankú","orcid":"0000-0002-8123-4065","position":20,"is_corresponding":false},{"id":266116,"name":"Ecaterina E. Dumbrava","orcid":"0000-0002-1959-0536","position":0,"is_corresponding":true}],"reference_count":41,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T23:44:39.550981Z","pmid":"34479035","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}